How people get it: Not approved for use in people. Sold online and by some clinics.
FDA status, evidence and safety
Sold online, not approvedNot approved; sold online. A draft HHS policy says it won't act against pharmacies that make it under set conditions
- FDA status
- Not FDA-approved. FDA listed BPC-157 among substances that may pose significant safety risks in compounding (its “category 2”), then moved it to a list of withdrawn nominations. In July 2026 FDA advisers voted to add it to the substances pharmacies may use. On October 30, 2026 HHS published a draft policy: it does not intend to act against pharmacies and doctors that compound BPC-157 under set conditions, as injections under the skin or into muscle, by mouth or on the skin, while that list is worked out. That is not an approval. It covers only compounding for a patient's prescription, with peptide from an FDA-registered maker; HHS says it aims to move people away from research-use-only peptides from foreign suppliers to a more controlled alternative. FDA safety-risk list ↗FDA compounding list ↗FDA advisers ↗Federal Register ↗HHS ↗
- FDA advisers, July 2026
- The FDA's compounding advisory committee recommended adding it to the substances pharmacies may use, for ulcerative colitis (8–6, 1 abstaining). The FDA hasn't decided. What's changing →
- What's changing
- A draft HHS policy, published October 30, 2026: no action against pharmacies that compound it under set conditions while the pharmacy list is worked out. Comments are open for two weeks. See what's changing →
- In people so far
- A 2026 systematic review found three human studies (30 people): knee pain injections, a bladder condition and an intravenous safety test in 2 people. All were of poor quality; the authors said it shouldn't be used outside proper clinical trials. PubMed ↗
- A trial after rotator cuff surgery is registered but not yet recruiting. ClinicalTrials.gov ↗
- Safety
- The FDA says it has little or no safety information on BPC-157, which may cause immune reactions and contain impurities, so it can't tell whether it would harm people. FDA safety-risk list ↗
- Sold online without a prescription; doctors warn of contamination, impurities and inaccurate doses. PubMed ↗
- In sport
- Banned in sport at all times: WADA names BPC-157 among non-approved substances (class S0). WADA ↗
One of the peptides we follow. We don't give doses or say where to buy. Talk to your doctor before trying any of them.
The basics
What it is
A review of studies says BPC-157 is a lab-made peptide (a short chain of amino acids).
What people use it for
A review of studies says BPC-157 is popular among athletes for recovering from muscle and bone injuries.
What the research has found so far
A review of studies found only three small human studies, covering knee pain, bladder inflammation, and an intravenous safety test.
Studied almost only in animals.
On BPC-157 peptide and aging, PubMed lists 0 trials in people, 1 studies that watched people over time, 202 animal and lab studies. See the counts and searches
Stage 2 because 4 registered trials in people have been found, but no large ones yet.
A stage shows how far research has got, not whether it will work for you. How stages work
Side effects and risks
A review of studies reported no treatment-related side effects in the three small studies, which were of poor quality.
Who should be careful, and drug interactions
The review rated the overall certainty of the evidence as very low.
Approval and legal status
A review of studies says BPC-157 lacks regulatory approval for human use, and evidence is largely limited to animal models.
Amounts used in studies
What studies or labels describe, not a recommendation.
Studies have used injections into the knee joint, a solution placed in the bladder, and intravenous (into a vein) forms.
Roughly what it costs
We don't have prices for this yet.
Questions to ask your doctor
- Is BPC-157 peptide a sensible option for me, given my health and the medicines I take?
- Could BPC-157 peptide interact with any medicine or supplement I already take?
- What side effects should I watch for, and when should I stop or call you?
- How would we tell whether it is helping, and when should we review it?
This is general information gathered from the sources listed, not medical advice. Talk to your doctor before starting anything new.
What experts say
No expert views collected yet. Each one we add names the person and links to where they said it.
What others are writing
Recent articles about BPC-157 peptide from health journalists, hospitals and universities. We link to them; we don't write or endorse them.
People say these peptides hurt them. Their stories are muffled in MAHA's push for medical freedom ↗
“He had taken BPC-157, a peptide drug popularized by podcasts about wellness, longevity, and what's called "body optimization.”
Patients report bad reactions to BPC-157, an unapproved peptide promoted by influencers despite lacking clinical trial data.
What You Need To Know About BPC-157 ↗
“BPC-157 is a synthetic peptide, a short chain of amino acids created in a lab. It's based on a substance found in gastric juices.”
The article says BPC-157 is an experimental, unapproved peptide with no proven human benefits or established safety, and advises talking to a provider first.
From Croatia to MAHA: How an unapproved drug became the next hot peptide ↗
“Almost all the existing data on BPC-157 comes from a single group of researchers in Croatia. In rodents, the substance promotes the growth of new blood vessels and reduces inflammation, enhancing healing in tendons, ligaments, and muscle.”
The article says BPC-157 is touted for healing but rests on little human data and raises safety concerns.
Commentary in journals
Recent research
The Atlantic examines the broad healing claims surrounding BPC-157
The Atlantic asks whether there is anything BPC-157 can't cure.
Review of a stomach-derived peptide and other agents for liver injury in animal studies
This review looks at many possible liver treatments, mostly tested in lab animals.
Review of peptide products BPC-157 and TB-500 for joint and muscle recovery
This review found mostly animal and lab studies, plus one small human case series with no standard measures.
Few human studies exist for BPC-157, a peptide used in sports injury recovery
This review found only three small human studies of BPC-157, so the evidence is very weak.
A new gel made with BPC-157 and chitosan was tested in a lab
Researchers made a gel that holds the peptide BPC-157 and tested its physical traits and germ-fighting power.
Review of BPC 157 studies in rats and mice on blood-flow injury
Researchers reviewed past animal studies of BPC 157 for injury when blood flow returns to tissue.
Trials
None of the registered trials of BPC-157 peptide is one we have linked as aging-related yet.
ClinicalTrials.gov lists 4 registered trials that mention BPC-157 peptide, for any condition (the count in The science below). Here we show the ones about aging. See them all ↗
The science
Counted from PubMed and ClinicalTrials.gov on Oct 30, 2026, using one search for BPC-157 peptide in relation to aging. Each link opens the exact search.
- Randomized trials in people
- 0 search ↗
- Large trials (multicenter or phase 3)
- 0 search ↗
- Phase 3 trials
- 0 search ↗
- Trials in people
- 0 search ↗
- Studies that watched people over time
- 1 search ↗
- Animal and lab studies
- 202 search ↗
- Registered trials
- 4 search ↗
PubMed search used
("BPC-157"[tiab] OR "BPC 157"[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide"[tiab])
Counts are search results, so they include some records that only mention BPC-157 peptide. How we count
Cite or share this page
Longevity Progress. (n.d.). BPC-157 peptide: Research stage and evidence. Retrieved October 30, 2026, from https://longevityprogress.com/treatments/bpc-157
<iframe src="https://longevityprogress.com/embed/stage/bpc-157" title="BPC-157 peptide: research stage on Longevity Progress" width="340" height="72" style="border:0" loading="lazy"></iframe>
The badge shows this treatment's current research stage and links back here. It updates by itself when the stage changes.